Enanta Pharmaceuticals (ENTA) Revenue (2012 - 2026)

Enanta Pharmaceuticals (ENTA) has 15 years of Revenue data on file, last reported at $17.2 million in Q1 2026.

• For the quarter ending Q1 2026, Revenue rose 14.96% year-over-year to $17.2 million; the trailing twelve-month figure through Mar 2026 stood at $69.2 million (up 7.37% YoY), and the FY2025 full-year result was $65.3 million, down 3.42% from the prior year.
• Revenue for Q1 2026 stood at $17.2 million, down from $18.6 million in the prior quarter.
• Across five years, Revenue topped out at $23.6 million in Q4 2022 and bottomed at $14.6 million in Q3 2024.
• The 5-year median for Revenue is $18.0 million (2023), against an average of $18.0 million.
• The widest annual swing landed in 2023, when Revenue declined 23.67%; it then climbed 14.96% in 2026.
• A 5-year view of Revenue shows it stood at $23.6 million in 2022, then slipped by 23.67% to $18.0 million in 2023, then decreased by 5.8% to $17.0 million in 2024, then advanced by 9.76% to $18.6 million in 2025, then retreated by 7.82% to $17.2 million in 2026.
• The last three Revenue figures came in at $17.2 million (Q1 2026), $18.6 million (Q4 2025), and $15.1 million (Q3 2025), per Business Quant data.

Peer Comparison